References of "Expert Review of Pharmacoeconomics & Outcomes Research"
     in
Bookmark and Share    
Full Text
See detailCost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis
Hiligsmann, Mickaël ULg; Vanoverberghe, Marie ULg; Neuprez, Audrey ULg et al

in Expert Review of Pharmacoeconomics & Outcomes Research (2010), 10(4), 359-366

Strontium ranelate has recently been introduced for the prevention and treatment of osteoporosis in Europe and in many countries worldwide. This study aims to review the published cost-effectiveness ... [more ▼]

Strontium ranelate has recently been introduced for the prevention and treatment of osteoporosis in Europe and in many countries worldwide. This study aims to review the published cost-effectiveness literature pertaining to strontium ranelate. Six studies were identified: two in United Kingdom, two in Belgium and two in Sweden. The findings were consistent across the literature, suggesting that strontium ranelate is a cost-saving drug for women with osteoporosis aged over 80 years of age, and it is a cost-effective treatment compared with no treatment for osteoporotic women aged over 70 years and for younger women with clinical risk factors for fragility fracture. Strontium ranelate was also shown to be cost-effective compared with branded risedronate in osteoporotic women over 75 years. Further analyses are required to assess effectiveness and adherence to strontium ranelate in real-life settings, as well as to evaluate the cost-effectiveness of strontium ranelate in other countries and in populations of men. [less ▲]

Detailed reference viewed: 33 (2 ULg)
Full Text
See detailOvercoming problems with adherence to osteoporosis medication.
Rabenda, Véronique ULg; Reginster, Jean-Yves ULg

in Expert review of pharmacoeconomics & outcomes research (2010), 10(6), 677-89

Nonadherence to pharmacological treatment in osteoporosis is a well-recognized problem. As in other chronic diseases, adherence to osteoporosis treatment is poor, resulting in enormous burden on patients ... [more ▼]

Nonadherence to pharmacological treatment in osteoporosis is a well-recognized problem. As in other chronic diseases, adherence to osteoporosis treatment is poor, resulting in enormous burden on patients and healthcare resources. Most importantly, low adherence rates consistently result in increased rates of fractures. However, it seems that efforts to evaluate and improve rates of both compliance and persistence are increasing. The extension of dosing intervals may be an element, among others, allowing improvements in therapeutic adherence. Improved patient education, enhancing healthcare provider-patients interaction, taking into account patient's preferences and involving them in treatment decisions may improve adherence. [less ▲]

Detailed reference viewed: 13 (2 ULg)